# Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma

> **NCT00255255** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 120 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/Formoterol

## Key facts

- **NCT ID:** NCT00255255
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-12
- **Final completion:** 2007-06
- **Target enrollment:** 120 (—)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255255, "Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00255255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*